Health Catalyst, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
HCAT$1.44-4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Health Catalyst, Inc. Consolidated Balance Sheets
Consolidated Balance Sheets
(in thousands, except share and per share data)
| As of December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $50,814 | $249,645 |
| Short-term investments | 44,918 | 142,355 |
| Accounts receivable, net(1) | 59,128 | 57,182 |
| Prepaid expenses and other assets | 14,447 | 16,468 |
| Total current assets | 169,307 | 465,650 |
| Property and equipment, net | 33,838 | 29,394 |
| Intangible assets, net | 77,678 | 86,052 |
| Operating lease right-of-use assets | 6,640 | 12,058 |
| Goodwill | 209,073 | 259,759 |
| Other assets | 6,107 | 6,016 |
| Total assets | $502,643 | $858,929 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $9,363 | $11,433 |
| Accrued liabilities | 18,697 | 26,340 |
| Deferred revenue(1) | 56,107 | 53,281 |
| Operating lease liabilities | 3,779 | 3,614 |
| Current portion of long-term debt | 1,627 | 231,182 |
| Total current liabilities | 89,573 | 325,850 |
| Long-term debt, net of current portion | 151,624 | 151,178 |
| Deferred revenue, net of current portion | 410 | 249 |
| Operating lease liabilities, net of current portion | 14,208 | 16,291 |
| Contingent consideration liabilities, net of current portion | 250 | — |
| Other liabilities | 798 | 154 |
| Total liabilities | 256,863 | 493,722 |
| Commitments and contingencies (Notes 9 and 16) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024 | — | — |
| Common stock, $0.001 par value per share, and additional paid-in capital; 500,000,000 shares authorized as of December 31, 2025 and 2024; 72,027,332 and 64,043,799 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1,608,840 | 1,552,714 |
| Accumulated deficit | (1,364,646) | (1,186,672) |
| Accumulated other comprehensive income (loss) | 1,586 | (835) |
| Total stockholders’ equity | 245,780 | 365,207 |
| Total liabilities and stockholders’ equity | $502,643 | $858,929 |
(1)Includes amounts attributable to related party transactions. See Note 18 for further details.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.